Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

G. B. Kolyvanov; V. P. Zherdev; O. G. Gribakina; P. O. Bochkov; R. V. Shevchenko; A. A. Litvin; E. V. Blynskaya; V. V. Bueva

doi:10.1007/s10517-019-04587-w

Comparative Preclinical Pharmacokinetics and Bioavailability of Antidepressant GSB-106 Tablet Form

Authors: Kolyvanov G.B.¹, Zherdev V.P.¹, Gribakina O.G.¹, Bochkov P.O.¹, Shevchenko R.V.¹, Litvin A.A.¹, Blynskaya E.V.², Bueva V.V.²
Affiliations:
1. Laboratory of Pharmacokinetics
2. Laboratory of Finished Dosage Forms, V. V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences
Issue: Vol 167, No 5 (2019)
Pages: 637-640
Section: Article
URL: https://journals.rcsi.science/0007-4888/article/view/241978
DOI: https://doi.org/10.1007/s10517-019-04587-w
ID: 241978

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

Pharmacokinetics and relative bioavailability of antidepressant GSB-106 (hexamethylendiamide bis-(N-monosuccinyl-L-seryl-L-lysine) were determined in rabbits after single oral administration of the pharmaceutical substance and tablet mass. GSB-106 concentrations in the blood plasma were determined by HPLC-mass spectrometry. Relative bioavailability of GSB-106 tablet form was 160.79±24.33%.